TerminatedNot Applicable

Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment

United States48 participantsStarted 2012-10

Plain-language summary

Nucleotide anti-viral analogues, including adefovir and TDF, have demonstrated kidney toxicity in HIV/HBV co-infected patients and HBV mono-infected European patients. Investigators suspected similar kidney proximal tubular injury can also occur in HBV mono infected Asian patients receiving TDF treatment.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Nephrotoxic agents
✕. Parenteral aminoglycoside antibiotics
✕. Cidofovir
✕. Cisplatin
✕. Foscarnet
✕. IV amphotericin B
✕. IV pentamidine
✕. Oral or IV ganciclovir

What they're measuring

renal tubular dysfunction

Timeframe: at 144 week after treatment with antiviral

Trial details

NCT IDNCT01715987

SponsorNew Discovery LLC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Hepatitis B trials